Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 19;10(25):11622–11636. doi: 10.7150/thno.47533

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Retro-inverso form of BPIs showed enhanced intracellular stability and maintained biological activity. A. The sequences of the D-retro-inverso (DRI) forms of BCL10-P2 and BCL10-P4. B. Western blot showing BCL10 in HBL1 cells to compare the pharmacokinetics between BCL10-P4 and DRI-BCL10-P4 treatments. C. EM micrographs showing that DRI-BCL10-P2/P4 inhibited Bc10 filament formation in vitro. D. Dose-response curves of DRI-BCL10-P2/P4 in HBL1, TMD8 and OCI-LY1 cells. The GI50s are indicated. The experiments were performed independently in triplicate. The data are presented as the means ± SD. Statistics: one-way ANOVA with Dunnett's multiple comparison test. E. Western blot showing IKKβ, p-IKKβ, IκBα, and p-IκBα in the HBL1, TMD8 and OCI-LY1 cells treated with DRI-BCL10-P4 at the indicated concentrations for 12 h. F. Apoptosis rate was analysed by annexin V⁺/PI^- and annexin V⁺/PI⁺ staining of cells treated with DRI-BCL10-P4 for 24 h. The y axis shows the sum of the percentage of annexin V⁺/PI^- and annexin V⁺/PI⁺ cells. The data are reported as the mean ± SD of two independent experiments.